Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a
sometimes neglected, yet common, sign and symptom with a profound effect on instrumental …

An individualized innovative disease management is of great importance for people with
multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative disease of the
central nervous system characterized by demyelination and axonal damage. Diagnosis and …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Treatment of multiple sclerosis (MS) has become increasingly multifaceted and comprises
not only a variety of disease-modifying drugs with different mechanism of action but also a …

Multiple sclerosis (MS), a putative autoimmune disease of the central nervous system (CNS),
commonly presents as relapsing-remitting MS (RRMS), characterized by recurrent episodes …

Over the last few decades, the improved diagnostic criteria, the wide use of MRI, and the
growing availability of effective pharmacologic treatments have led to substantial advances …

One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical
manifestations and progression trajectories. It still remains to be elucidated whether this …